Glycilock Trio 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg), designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glycemic control. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, minimizing postprandial hyperglycemia. This synergistic combination addresses multiple pathophysiological defects in type 2 diabetes, offering improved glycemic regulation. Glycilock Trio 2 Tablet SR is formulated as a sustained-release tablet to provide a prolonged therapeutic effect and enhance patient compliance by reducing dosing frequency. It is indicated for patients inadequately controlled on monotherapy or dual therapy with these agents. The medication should be used under medical supervision, with regular monitoring of blood glucose levels and renal function. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in cases of diabetic ketoacidosis or hypersensitivity to any component. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rarely, lactic acidosis.